Dynamical Modelling of Bone Formation and Resorption under Impulsive Estrogen Supplement: Effects of Parathyroid Hormone and Prolactin

Supassorn Aekthong¹ and Chontita Rattanakul²

¹Department of Mathematics, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
²Centre of Excellence in Mathematics, Commission on Higher Education, Bangkok 10400, Thailand

Correspondence should be addressed to Chontita Rattanakul; chontita.rat@mahidol.ac.th

Received 21 September 2021; Accepted 1 December 2021; Published 15 December 2021

Academic Editor: Hernando Quevedo

Copyright © 2021 Supassorn Aekthong and Chontita Rattanakul. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Osteoporosis, a bone metabolic disease, is one of the major diseases occurring in aging population especially in postmenopausal women. A system of impulsive differential equations is developed in this paper in order to investigate the effects of parathyroid hormone and prolactin on bone-forming cells, namely, osteoblasts, and bone-resorbing cells, namely, osteoclasts, under the impulsive estrogen supplement. The theoretical analysis of the developed model is carried out so that we obtain the conditions on the system parameters in which the stability and permanence of the model can occur. Computer simulations are also provided to illustrate the theoretical predictions.

1. Introduction

Osteoporosis is a disease which shows no symptoms until there is a bone fracture incidence [1]. It is characterized by an impairment of bone mass, measured by a Bone Mineral Density (BMD) test as the T-score is less than or equal to 2.5, and microarchitectural deterioration of bone tissue [2–5]. This disease causes a major public health issue for all races and both sexes [1]. Since BMD decreases as the population ages, osteoporosis occurs prevalently in menopause woman and elderly men between 75 and 80 years of age [6]. More than 200 million people worldwide were approximated to be osteoporotic patients with hip fractures [7]. In Europe and the United States, a report revealed that 30% of women are diagnosed with osteoporosis [8]. It was reported in Thailand that 19.8% of postmenopausal women are prevalently osteoporotic [9]. Furthermore, approximately 40% of women who experience menopause and 30% of men might have an osteoporosis-related fracture in the remaining lifetime [10].

Bone is a living tissue [11]. There is a process in its place to resorb old bone and form new bone to maintain its strength and health, called bone-remodeling process, and such a process occurs throughout a person’s life [10, 12, 13]. In osteoporosis patients, the loss of bone mass occurs because the removal of older bone is more than the replacement of new bone which is an imbalance between bone resorption and bone formation [10]. There are two families of cells mainly involved in the process of bone remodeling, namely, osteoclastic cells, breaking down the bone cells, and osteoblastic cells, forming the bone tissue [12, 13]. Bone-remodeling process is composed of four phases sequentially, which are activation, resorption, reversal, and formation [12]. In this process, osteoblast lineage cells play a crucial role in the activation stage by taking action on blood cell precursors or hematopoietic cells to establish osteoclastic resorption of bones. Under a layer of lining cells, the removal of bone is done by osteoclasts in the resorption step. The mineral here is dissolved, and the bone matrix is broken down. In the reversal phase, the surface of the resorbed bone creates a thin layer of protein to make it ready for the following stage. Finally, in the formation step, osteoblasts acting in successive waves start to form up new bones by
laying down multiple layers of matrix in an orderly arrangement. Then, some of these osteoblasts stay inside the bone and become osteocytes, remaining in contact to adjacent osteocytes and osteoblasts on the bone surface. This process is successfully finished in 3-4 months, while the first three stages take 2 to 3 weeks to finish [12]. There are many factors involved in bone-remodeling process such as parathyroid hormone (PTH), prolactin (PRL), calcitonin, and estrogen.

PTH plays an important role in the bone-remodeling process [14]. It is released from the parathyroid gland, and both stimulating and inhibiting effects have been reported on the development of osteoblasts from its progenitors [14–18]. On the one hand, PTH indirectly enhances the development of osteoclasts from its progenitors by operating through osteoblasts since osteoclasts lack PTH receptors while preosteoblast precursors and preosteoblasts possess them [14–18]. On the other hand, PRL is a polypeptide hormone synthesized in and secreted from specialized cells of the anterior pituitary gland, the lactotrophs [19]. According to [20], PRL receptors have been reported on osteoblasts, and hence, PRL then has effects on bone-remodeling process as well. PRL enhances bone resorption by increasing receptor activator of NF-κ-ligand (RANKL) and decreasing osteoprotegerin (OPG) expressions by osteoblastic cells [21].

Bone mass reduces significantly due to the declining secretion of estrogen during and after the menopause years in women [22]. Estrogen deficiency in postmenopausal women leads to accelerating resorption of bone by osteoclasts and osteoporosis will then occur [23]. The direct and indirect studies indicated that estrogen also plays a key role on skeletal health in men [24]. Several hormones play an important role in the process of bone remodeling and also in the treatments of osteoporotic patients. Estrogen replacement therapy has a beneficial effect on postmenopausal women in preventing the loss of bone as shown in clinical studies [25, 26]. In a long-term study of following up postmenopausal women who take estrogen replacement therapy, in vivo study results demonstrated that replacement estrogen therapy can prevent or slow down osteoporosis in postmenopausal patients compared to an unsupplemented control group [27]. A recent research using cancellous rats reported that decreased estrogen levels led to bone changes which affect flow of interstitial around osteocytes [28]. Many studies have shown that estrogen impacts positively in improving bone mineral density, and taking lower doses of estrogen is shown to be effective and cause fewer side effects. At the cellular level, estrogen increases the level of OPG which is able to bind with RANKL to block the differentiation, the activity, and the survival of osteoclasts.

Since bone is an alive and dynamic tissue [11], many researchers have been trying to describe the process of bone remodeling inside our bodies using several types of mathematical models. Chudtong et al. [29] introduced an impulsive system to describe bone-remodeling process involving PTH supplements by extending Rattanakul et al.’s model in [30]. Rattanakul et al. [31] constructed a mathematical model as a system of nonlinear differential equations to investigate bone formation and resorption process based on the effect of calcitonin. Motivated by [31], Panitsupakamon and Rattanakul [32] modified the model proposed in [31] by incorporating the time delay observed in the bone-remodeling process. The influence of estrogen supplement is also considered by adding a term to the dynamics of the active osteoclast population in the modified model. Chaiya and Rattanakul [33] proposed an impulsive mathematical model of bone-remodeling process incorporating the effects of prolactin and the impulsive control strategies of parathyroid hormone supplement on osteoblasts and osteoclasts. The dosage of parathyroid hormone can be added appropriately to the system to ensure the suitable levels of active osteoblasts and active osteoclasts. They also proposed another model accounting for the effects of PTH and calcitonin on bone-remodeling process together with the effects of impulsive treatments of estrogen in [34]. However, a mathematical model of bone resorption and bone formation consisting of osteoblastic cells, osteoclastic cells, parathyroid hormone, and prolactin with the effect of impulsive treatment of estrogen has never been established.

2. Model Development

In this section, we propose the following impulsive differential equation model to investigate the dynamics of bone-forming cells and bone-resorbing cells based on the effects of PTH, PRL, and estrogen supplements:

\[
\begin{align*}
\frac{dx}{dt} &= \frac{a_1}{k_1 + z} + a_2 y - b_1 x, \\
\frac{dy}{dt} &= \frac{a_3}{k_2 + z} + a_4 x - b_2 y, \\
\frac{dz}{dt} &= \left[ \frac{a_5 x}{(k_3 + x^3)} + \frac{a_6 y}{(k_4 + y^3)} \right] w - b_3 z, \\
\frac{dw}{dt} &= a_7 x - \frac{a_8 x w}{k_5 + x} - \frac{a_9 y w}{k_6 + y} - b_4 w,
\end{align*}
\]

with

\[
\begin{align*}
\Delta z(t) &= -\rho z(t), \\
\Delta w(t) &= \mu, \\
t &= nT,
\end{align*}
\]

where \( \Delta z(t) = z(t^*) - z(t) \) and \( \Delta w(t) = w(t^*) - w(t) \). In what follows, \( x(t), y(t), z(t), \) and \( w(t) \) account for the level of PTH in blood at time \( t \), the level of PRL in blood at time \( t \), the number of active osteoclasts at time \( t \), and the number of active osteoblasts at time \( t \), respectively. \( T \) accounts for the period between each impulsive estrogen treatment, \( n \in \mathbb{Z}_+ = \{1, 2, 3, \ldots\} \), \( \rho \) accounts for the inhibiting effect of estrogen treatment on osteoclasts, \( 0 < \rho < 1 \), and \( \mu \) accounts for the stimulating effect on osteoblasts of estrogen treatment, \( \mu > 0 \). In addition, all parameters in (1) and (2) are assumed to be positive.
PTH secretion from the parathyroid gland is controlled by the calcium level in blood. Once the number of active osteoclasts increases, blood calcium levels then increase due to the increase in bone resorption resulting in the decrease of PTH secretion in order to maintain calcium level within the normal range [35, 36]. Hence, we then assumed that the rate of change of the concentration of PTH in blood at time \( t \) denoted by \( \frac{dx}{dt} \) in equation (1) varies inversely with the number of active osteoclasts as shown in the first term on the right-hand side of the first equation in equation (1).

According to [37], an increase in the level of plasma PRL also enhances the release of PTH from the parathyroid gland and hence the second term on the right-hand side denotes the stimulating effect of PRL on PTH. The last term stands for the removal rate of PTH from the system.

However, PRL stimulates osteoclastic differentiation by decreasing OPG and increasing RANKL expressions by osteoblastic cells [21]. RANKL then binds to RANK, its receptor on preosteoclast, and stimulates the differentiation of osteoclasts. To balance the bone-remodeling cycle, when the number of osteoclasts increases, the secretion of PRL is then decreased. In the second equation of (1), the rate of change of the level of PRL in blood denoted by \( \frac{dy}{dt} \) is then assumed to vary inversely with the number of active osteoclasts as shown in the first term on the right-hand side. On the other hand, the increase in the number of osteoclasts leads to the increase in the calcium level in blood and then the secretion of PTH from the parathyroid gland, as well as the secretion of PRL from the anterior pituitary gland, which also enhances the secretion of PTH will be decreased in order to maintain the calcium level in blood within the normal range [35, 36]. Hence, we then assumed that the rate of change of the number of active osteoclasts as denoted by \( \frac{dx}{dt} \) in equation (1), the rate of change of the number of active osteoclasts is inversely proportional to the number of osteoclasts.

Osteoclasts lack PTH and PRL receptors, whereas osteoblasts possess them. Therefore, the effects of PTH and PRL on the differentiation of osteoclasts are both indirect effects. However, it has been reported in [17] that the differentiation of active osteoclasts also requires the production of osteoclast differentiation factor (ODF) and its receptor on osteoclasts as well and hence the differentiation of active osteoclasts requires the presence of both osteoblastic and osteoclastic cells. Even though PTH has the stimulating effects on the differentiation of active osteoclasts as reported in [18, 38], it has also been observed clinically in [17] that PTH inhibits the differentiation of active osteoclasts when the level of PTH increases further as well. On the other hand,

\[
x = -\frac{a_1b_2}{A(k_1 + z)} + \frac{a_3a_4}{b_2(k_2 + z)} \equiv f_1(z)
\]

and

\[
y = \frac{a_3}{b_2(k_2 + z)} + \frac{a_4f_1(z)}{b_2} = \frac{a_3}{b_2(k_2 + z)} + \frac{a_3a_4}{A(k_2 + z)} + \frac{a_1a_4}{b_2(k_2 + z)} + \frac{a_2a_3a_4}{Ab_2(k_2 + z)} \equiv f_2(z),
\]

where \( A = b_1b_2 - a_2a_4 \) with \( b_1b_2 > a_2a_4 \).

Thus, the reduced system of (1) and (2) can be obtained as follows:

\[
x = -\frac{a_1b_2}{A(k_1 + z)} + \frac{a_3a_4}{b_2(k_2 + z)} \equiv f_1(z)
\]

\[
y = \frac{a_3}{b_2(k_2 + z)} + \frac{a_4f_1(z)}{b_2} = \frac{a_3}{b_2(k_2 + z)} + \frac{a_3a_4}{A(k_2 + z)} + \frac{a_1a_4}{b_2(k_2 + z)} + \frac{a_2a_3a_4}{Ab_2(k_2 + z)} \equiv f_2(z),
\]
Now, we let
\[ t, S \]

\[ U \]

\[ \Delta z(t) = -\rho z(t), \]
\[ \Delta w(t) = \mu, \]
\[ t = nT. \]
\[ (6) \]

Lemma 1. For all \( t \geq 0 \), the solution of systems (5) and (6), \( S(t) = (z(t), w(t)) \), is nonnegative provided that \( S(0^+) \geq 0 \). In addition, \( S(t) \) is positive for all \( t \geq 0 \) provided that \( S(0^+) > 0 \).

Lemma 2. Suppose that \( (z(t), w(t)) \) is a solution to (5) and (6) and
\[ b_4 > \frac{a_3M_3}{k_3} + \frac{a_4M_4}{k_4} \]
\[ (10) \]

Then, for sufficiently large \( t \), there exists a positive constant \( M \) such that \( z(t) \leq M \) and \( w(t) \leq M \).

Proof. Let \( u(t) = z(t) + w(t) \), \( \sup f_1(z) = M_1 \), \( \sup f_1(z) = (1/A)(a_3b_2 + a_3a_4) = M_3 \), \( \sup f_2(z) = (a_3/b_2) + (a_3a_4/A) + (a_3a_4/Ab_2) = M_4 \), and \( c = \min\{b_3, b_4\} - (a_5M_3/k_3) - (a_5M_4/k_4) \).

For \( t \neq nT \), it follows that
\[ D^*u + cu = \frac{dz}{dt} + \frac{dw}{dt} + cz + cw \]
\[ \leq \left[ \frac{a_5f_1(z)}{k_3 + f_1^2(z)} + \frac{a_6f_2(z)}{k_4 + f_2^2(z)} \right] zw - b_3z + a_7f_1(z) \]
\[ - \frac{a_8f_1(z)w}{k_3 + f_1(z)} - \frac{a_9f_2(z)w}{k_6 + f_2(z)} - b_4w + cz + cw \]
\[ \leq \left[ \frac{a_5z f_1(z)}{k_3 + f_1^2(z)} + \frac{a_6z f_2(z)}{k_4 + f_2^2(z)} \right] w + (c - b_3)z + (c - b_4)w + a_7M_1 \]
\[ \leq \left[ \frac{a_5M_3}{k_3} + \frac{a_6M_4}{k_4} + c - b_4 \right] w + (c - b_3)z + a_7M_1 \]
\[ \leq a_7M_1 \equiv M_0, \]
\[ (11) \]

Thus, \( D^*u \leq -cu + M_0 \). For \( t = nT \), we can see that
\[ u(nT^+) = z(nT^+) + w(nT^+) \]
\[ = (1 - \rho)z(nT) + \mu + w(nT) \]
\[ = z(nT) + w(nT) + \mu - \rho z(nT) \]
\[ \leq u(nT) + \mu. \]  

By applying Lemma 2.2 in [44], it can be derived that

\[
\frac{dw}{dt} = B - Cw, \quad t \neq nT, \\
w(nT^+) = w(nT) + \mu, \quad t = nT, \\
w(0^+) = w_0,
\]  

where \( B = a_2f_1(0), C = (a_3/L_2 + f_1(0)) + (a_4/k_4) \) and \( f_2(0) = a_3/L_2 + f_1(0) + b_4f_1(0) + b_5f_2(0) + b_6f_3(0) + b_7f_4(0) + b_8f_5(0) + b_9f_6(0) + b_{10}f_7(0) + b_{11}f_8(0) + b_{12}f_9(0) + b_{13}f_{10}(0)/k_4 \).  

It is obvious that \( B \) and \( C \) are positive provided that \( b_1 > b_2 > a_2 \). By solving system (14), we obtain its periodic solution as follows:

\[
\bar{w}(t) = \frac{\mu e^{-C(T-nT)}}{1 - e^{-C}} + B \quad t \in (nT, (n+1)T],
\]  

such that \( \bar{w}(0^+) = \mu / (1 - e^{-CT}) + B/C > 0 \).

Therefore, the positive solution to system (14) can be written as

\[
w(t) = \left( w_0 - \frac{B}{C} \right) e^{-Ct} + \bar{w}(t), \quad t \in (nT, (n+1)T].
\]

Lemma 3. System (14) has a positive periodic solution \( \bar{w}(t) \). In addition, the solution \( w(t) \) of (14) converges to \( \bar{w}(t) \) as \( t \to \infty \).

Therefore, \( u(t) \leq M \) as \( t \to \infty \) and \( u(t) \) is uniformly ultimately bounded, which means that when \( t \) is large enough with \( z(t) \leq M \) and \( w(t) \leq M \) for some positive constant \( M \).

Let us consider the following reduced impulsive system of (5) and (6) when osteoclasts are absent (\( z = 0 \)):

\[
\frac{dw}{dt} = B - Cw, \quad t \neq nT, \\
w(nT^+) = w(nT) + \mu, \quad t = nT,
\]  

Hence, the positive periodic solution to systems (5) and (6) in the absence of osteoclasts is

\[
(0, \bar{w}(t)) = \left( 0, \frac{\mu e^{-C(t-nT)}}{1 - e^{-CT}} + \frac{B}{C} \right),
\]  

for \( t \in (nT, (n+1)T] \) with \( \bar{w}(nT^+) = \bar{w}(0^+) = \mu / (1 - e^{-CT}) + (B/C), n \in \mathbb{Z}^+ \).

Theorem 1. The solution \( (0, \bar{w}(t)) \) of systems (5) and (6) is locally asymptotically stable if

\[
0 < T < T_{max},
\]  

\[
\frac{D\mu}{C} < \ln \left( \frac{1}{1 - \rho} \right),
\]  

where \( D = (a_2f_1(0)/k_4 + f_1(0)) + (a_4/k_4) \) and \( T_{max} \equiv \left( 1/(DB/C - b_2) \right) \ln (1/1 - \rho) - D\mu/C \).

Proof. The local stability of the solution \( (0, \bar{w}(t)) \) may be determined by considering the behavior of small amplitude perturbations of the solution.

Here, we let

\[
z(t) = u_1(t), \\
w(t) = \bar{w}(t) + u_2(t).
\]

It follows that

\[
\begin{pmatrix}
  u_1(t) \\
u_2(t)
\end{pmatrix} = \Phi(t) \begin{pmatrix}
  u_1(0) \\
u_2(0)
\end{pmatrix}, \quad 0 < t < T,
\]  

where

\[
\Phi(t) = e^{t\Phi}.
\]
where $\Phi(t)$ is the fundamental solution matrix, in which
\[
\frac{d\Phi(t)}{dt} = \begin{pmatrix} D\vec{u}(t) - b_3 & 0 \\ \ast & -C \end{pmatrix} \Phi(t),
\]
and $\Phi(0)$ is the identity matrix $I$.

Thus, we obtain the fundamental solution matrix as follows:
\[
\Phi(t) = \begin{pmatrix} e^\int_0^t(D\vec{u}(s) - b_3)ds & 0 \\ \ast & e^\int_0^t(-C)ds \end{pmatrix}.
\]

Note that the terms $\ast$ and $\ast\ast$ are not required in further analysis and their exact expressions are not necessary.

Linearization of (6) provides
\[
\begin{pmatrix} u_1(t) \\ u_2(t) \end{pmatrix} = \begin{pmatrix} 1 - \rho & 0 \\ 0 & 1 \end{pmatrix} \begin{pmatrix} u_1(0) \\ u_2(0) \end{pmatrix}.
\]

Next, the Floquet theory is then applied to guarantee the local stability of the solution $(0, \vec{u}(t))$.

Let us consider
\[
M = \begin{pmatrix} 1 - \rho & 0 \\ 0 & 1 \end{pmatrix} \Phi(T).
\]

The solution $(0, \vec{u}(t))$ is locally asymptotically stable if the magnitudes of $\lambda_1$ and $\lambda_2$ and the eigenvalue of $M$ are both less than 1.

We can see that
\[
\lambda_1 = (1 - \rho)e^\int_0^t(D\vec{u}(s) - b_3)ds = (1 - \rho)e^{(D\vec{u}(C) - DBT)(C) - b_3T},
\]
\[
\lambda_2 = e^\int_0^t(-C)ds = e^{-CT}.
\]

Since $0 < \rho < 1$ and $C > 0$, it follows that $|\lambda_1| < 1$ provided that (18)-(20) are satisfied. Also, it is obvious that $|\lambda_2| < 1$, and hence, the proof is complete.

\section{4. Permanence of the System}

\textbf{Definition 2.} Systems (5) and (6) are said to be permanent if there exist positive constants $m, M, t_0$ such that for all solutions $(z(t), w(t))$ with positive initial values $z(0^+)$ and $w(0^+)$ the following conditions hold for all $t > t_0 > 0$:
\[
m \leq z(t) \leq M,
\]
\[
m \leq w(t) \leq M.
\]

\textbf{Theorem 2.} Suppose that
\[
T > T^*,
\]
where $T^* \equiv (1/(DB/C) - b_3)\ln(1/1 - \rho)$. Systems (5) and (6) are permanent provided that (10), (19), and (30) hold.

\textbf{Proof.} Let $S(t) = (z(t), w(t))$ be any solution of (5) and (6) with $z(0^+) > 0$ and $w(0^+) > 0$. Suppose that (10) holds; it follows that when $t$ is large enough, $z(t) \leq M$ and $w(t) \leq M$ for some $M > 0$ according to Lemma 2.

Consider the second equation of (5); we can see that
\[
\frac{dw}{dt} \geq \frac{a_1f_1(z)w - a_2f_2(z)w}{k_5 + f_1(z)} - \frac{a_1f_3(z)w}{k_6 + f_2(z)} - b_4w, \quad t \neq nT,
\]
\[
w(nT^+) = w(nT) + \mu, \quad t = nT.
\]

It follows that for sufficiently large $t$, there exists $\varepsilon > 0$ such that
\[
w(t) > \frac{B}{C} + \vec{w}(t) - \varepsilon.
\]

Therefore, we obtain
\[
w(t) > \frac{B}{C} + \vec{w}(t) - \varepsilon \equiv m_1,
\]
when $t$ is large enough.

Next, we will show that there is a positive constant $m_2$ for which $z(t) > m_2$. Firstly, for some $m_3 > 0$, we let
\[
\begin{align*}
\bar{M}_1 &= \frac{a_1f_1(m_1)}{(k_3 + f_1(m_3))} + \frac{a_2f_2(m_1)}{(k_4 + f_2(m_3))}, \\
\bar{M}_2 &= \frac{a_1a_3b_2k_3 + a_2a_3a_4k_1}{CA(k_1 + m_3)(k_2 + m_3)}.
\end{align*}
\]

Secondly, we will do the following two steps. \qed

\textbf{Step 1.} We will show that $z(t_1) \geq m_3$ for some $t_1 > 0$ by contradiction.

Suppose that $z(t) < m_3$ for all positive values of $t$. From the second equation of (5) and (6), we can see that
\[
\frac{dw}{dt} \geq \frac{a_1f_1(z)w - a_2f_2(z)w}{k_5 + f_1(z)} - \frac{a_1f_3(z)w}{k_6 + f_2(z)} - b_4w, \quad t \neq nT,
\]
\[
\geq \frac{a_1a_2b_2k_3 + a_2a_3a_4k_1}{A(k_1 + m_3)(k_2 + m_3)} - Cw,
\]
\[
w(t^*) = w(t) + \mu, \quad t = nT.
\]

Let us consider the following comparison system:
\[
\frac{dP}{dt} = \frac{a_1a_2b_2k_1 + a_3a_3a_4k_1}{A(k_1 + m_3)(k_2 + m_3)} - CP, \quad t \neq nT,
\]
\[
P(t^+) = P(t) + \mu, \quad t = nT,
\]
\[
P(0^+) = w(0^+).
\]
A periodic solution of (29) can then be obtained as follows:
\[
P(t) = \frac{\mu e^{-C(t-nT)}}{1 - e^{-CT}} + \frac{a_1a_2b_2k_1 + a_3a_3a_4k_1}{CA(k_1 + m_3)(k_2 + m_3)}, \quad t \in (nT, (n+1)T),
\]
with \(P(0^+) \equiv \mu/1 - e^{-CT} + B/C\). Therefore, the positive solution of (29) is
\[
P(t) = \left( P(0^+) - \frac{a_1a_2b_2k_1 + a_3a_3a_4k_1}{CA(k_1 + m_3)(k_2 + m_3)} - \frac{\mu}{1 - e^{-CT}} \right) e^{-CT} + P(t).
\]
Note that \(f_1(m_3) = (a_1b_2/A(k_1 + m_3)) + (a_3a_4/A(k_2 + m_3))\) and \(f_2(m_3) = (a_1b_2/k_1 + m_3) + (a_3a_4/k_2 + m_3)\).
From the first equation of reduced system (5), we have
\[
\frac{dz}{dt} = \left[ \frac{a_5f_1(z)}{(k_3 + f_1^2(z))} + \frac{a_6f_2(z)}{(k_4 + f_2^2(z))} \right] w - b_3z 
\geq \left[ \frac{a_5f_1(m_3)}{(k_3 + f_1^2(m_3))} + \frac{a_6f_2(m_3)}{(k_4 + f_2^2(m_3))} \right] w - b_3z 
= (\tilde{M}_1 w - b_3) z.
\]
According to the comparison theorem [45], we obtain \(w(t) \geq P(t)\). It follows that
\[
P(t) - \varepsilon_1 < P(t) \leq w(t), \quad t \neq nT, t \geq T_1,
\]
for some \(T_1 > 0\) and for \(\varepsilon_1 > 0\) which is small enough.
Hence,
\[
\frac{dz}{dt} \geq (\tilde{M}_1 (P(t) - \varepsilon_1) - b_3) z, \quad t \neq nT, t \geq T_1,
\]
\[
z(t^+) = (1 - \rho) z(t), \quad t = nT, t \geq T_1.
\]
Suppose that \(n \in \mathbb{Z}_+\) and \(NT \geq T_1\). Then, by integration over \((nT, (n+1)T], n \geq N\), we obtain
\[
z((n+1)T) \geq z(nT)(1 - \rho) e\left\{ \int_{nT}^{(n+1)T} \left[ (\tilde{M}_1 (P(t) - \varepsilon_1) - b_3) \right] dt \right\}
\geq z(nT)(1 - \rho) e\left\{ (\tilde{M}_1 \tilde{M}_2 - \tilde{M}_1 \varepsilon_1 - b_3) T + (\tilde{M}_1 \tilde{M}_2 - \tilde{M}_1 \varepsilon_1 - b_3) T \left( \tilde{M}_1 \tilde{M}_2 \mu/C \right) \right\}
= z(nT) e^{\tilde{M}_1 \varepsilon_1 - b_3} T + (\tilde{M}_1 \tilde{M}_2 \mu/C),
\]
where
\[
\eta \equiv (1 - \rho) \ e^{(\tilde{M}_1 \tilde{M}_2 - \tilde{M}_1 \varepsilon_1 - b_3) T + (\tilde{M}_1 \tilde{M}_2 \mu/C)}.
\]
We can see that
\[
\ln \eta = \ln (1 - \rho) + \left( (\tilde{M}_1 \tilde{M}_2 - \tilde{M}_1 \varepsilon_1 - b_3) T + (\tilde{M}_1 \tilde{M}_2 \mu/C) \right).
\]
Then, for a positive constant \(\varepsilon_1\) which is sufficiently small, we have
\[
\ln \eta \approx \ln (1 - \rho) + \left( (\tilde{M}_1 \tilde{M}_2 - \tilde{M}_1 \varepsilon_1 - b_3) T + (\tilde{M}_1 \tilde{M}_2 \mu/C) \right) > \ln (1 - \rho) + (\tilde{M}_1 \tilde{M}_2 - b_3) T
\]
\[
= (\tilde{M}_1 \tilde{M}_2 - b_3) T - \ln \left( \frac{1}{1 - \rho} \right).
\]
Therefore, if (19) and (30) hold, then a small positive constant \(m_3\) can be chosen so that \(\ln \eta > 0\), and hence \(\eta > 1\). It follows that \(z((n+k)T) \geq z(nT)^k \rightarrow \infty\) when \(k \rightarrow \infty\) which contradicts the boundedness of \(z(t)\). Hence, there exists \(T_1 > 0\) such that \(z(t_1) \geq m_3\).

**Step 2.** If \(z(t) \geq m_3\) for all \(t \geq t_1\), then the proof is complete; otherwise, there exists \(t > t_1\) such that \(z(t) < m_3\) and we then let \(t^* = \inf\{z(t) < m_3\}\), so that the following two possible cases are obtained.

**Case 1.** There exists \(n_1 \in \mathbb{Z}_+\) such that \(t^* = n_1 T\). It follows that for \(t \in (t_1, t^*], z(t) \geq m_3\), and we obtain \(z(t) = m_3\) by the continuity of \(z(t)\). When \(t\) is large enough, \(z(t)\) and \(w(t)\) are both bounded above by a positive constant \(M\) and \(w(t)\) is also bounded below by a positive constant \(m_1\) which imply that we can choose positive constants \(M'\) and \(m'\) for which \(z(t) < M'\) and \(m' < w(t) < M'\) such that
\[
m' < \frac{b_3}{M_1}
\]
with
\[
w(t^*) = \frac{a_1a_2b_2k_1 + a_3a_4a_7k_1}{CA(k_1 + m_3)(k_2 + m_3)} - \frac{\mu}{1 - e^{-CT}} - \mu < M'.
\]
We also choose \(n_2, n_3 \in \mathbb{Z}_+\) that satisfy the following conditions:
\[
n_2T > \frac{1}{B} \ln \left( \frac{M' + \mu}{\varepsilon_1} \right)
\]
and
\[
(1 - \rho)^{n_2} e^{n_2 ((n_2+1)r) \eta} > 1,
\]
where
\[
\eta_1 \equiv \tilde{M}_1 m_1' - b_3 < 0.
\]
Here, we let \(T' = n_1 T + n_2 T\). We claim that there exists a constant \(t_2 \in (t^*, t^* + T')\) in which \(z(t_2) > m_3\). Otherwise, by considering (38) with \(P(t^*) = w(t^*)\) for \(t \in (nT, (n+1)T]\) and \(n_1 \leq n \leq n_2 + n_3\), we obtain
For \( n_3 T \leq t - t^* \leq T' \),

\[
\begin{align*}
|P(t) - \bar{P}(t)| &= \left| \frac{a_1 a_2 b_2 k_2 + a_2 a_3 a_3 k_1}{CA(k_1 + m_3)(k_2 + m_3)} - \frac{\mu}{1 - e^{-CT}} \right| e^{-C(t-t')} + \bar{P}(t).
\end{align*}
\]

(50)

Therefore, we obtain

\[
\begin{align*}
z(t^* + T') &\geq z(t^* + n_3 T) \eta^{n_3} \\
&\geq m_3 (1 - \rho)^{n_3} e^{\eta_l (n_3 + 1) T} \eta^{n_3} \\
&> m_3,
\end{align*}
\]

which is a contradiction, and hence, \( z(t_4) > m_3 \) for some \( t_4 \in (t^*, t^* + T'] \).

Next, we let \( \bar{t} = \inf\{z(t) > m_3\} \). It follows that \( z(t) < m_3 \) for \( t \in (t^*, \bar{t}) \), and we can obtain \( z(\bar{t}) = m_3 \) by the continuity of \( z(t) \). Then, \( l \in Z_+ \) is chosen where \( l \leq n_2 + n_3 \) and \( t^* + l T \geq \bar{t} \). Suppose \( t \in (t^* + (l-1) T, t^* + l T) \). From (54), we obtain

\[
\begin{align*}
z(t) &\geq z(t^* + (l-1) T) (1 - \rho)^{l-1} e^{\eta_l ((l-1) T + (l-1) T)} \\
&\geq m_3 (1 - \rho)^{l-1} e^{\eta_l (l T)} \\
&\geq m_3 (1 - \rho)^{n_2 + n_3} e^{\eta_l (n_2 + n_3) T}.
\end{align*}
\]

Since \( \eta_l \) is negative and \( l < n_2 + n_3 \), we let

\[
\bar{m}_2 = m_3 (1 - \rho)^{n_2 + n_3} e^{\eta_l (n_2 + n_3) T},
\]

so that \( z(t) \geq \bar{m}_2 \) for \( (t^*, \bar{t}) \). We can use \( \bar{t} \) instead of \( t^* \), the proof can be proceeded in the same manner and consequently, we will obtain \( z(t) \geq \bar{m}_2 \) for sufficiently large \( t \).

Case 2. \( t^* \neq n T \) for all \( n \in Z_+ \). Then, for \( t \in [t_1, t^*] \), we have \( z(t) \geq m_3 \) and \( z(t^*) = m_3 \). We assume that there exists \( n_1' \in Z_+ \) such that \( t^* \in (n_1' T, (n_1' + 1) T) \). This leads to the following two possible subcases:

Case 2.1: for all \( t \in (t^*, (n_1' + 1) T), z(t) \leq m_3 \). If there exists a constant \( t_2' \in [(n_1' + 1) T, (n_1' + 1) T + T'] \), then we can claim that \( z(t_2') > m_3 \). Otherwise, let us consider (38) with \( P((n_1' + 1) T') = w((n_1' + 1) T') \). For \( t \in (nT, (n + 1) T), n_1 + 1 \leq n \leq n_1' + 1 + n_2 + n_3 \), it follows that

By integrating (54) over \([t^*, t^* + n_2 T]\), it follows that

\[
\begin{align*}
z(t^* + n_2 T) &\geq z(t^*) e^{\eta_l (n_2 T)} \\
&\geq z(t^*) (1 - \rho)^{n_2} e^{\eta_l (n_2 T)} \\
&\geq m_3 (1 - \rho)^{n_2} e^{\eta_l (n_2 T)} \\
&\geq m_3 (1 - \rho)^{n_2} e^{\eta_l ((n_2 + 1) T)}.
\end{align*}
\]

(55)

By a similar argument in Case 1, we have

\[
|P(t) - \bar{P}(t)| < \epsilon_1,
\]

(56)

for \( n_2 T \leq t - t^* \). It follows that

\[
\bar{P}(t) - \epsilon_1 < P(t) \leq w(t).
\]

(57)
Since \( n_2 T \leq (n_1' + n_2)T - t^* \), we then have
\[
 z((n_1' + n_2)T) \geq z(t^*) e^{n_1 ((n_1' + n_2)T - t^*)} \\
\geq z(t^*) \left(1 - \rho\right) e^{n_1 ((n_1' + n_2)T - t^*)} \\
\geq m_3 \left(1 - \rho\right) e^{n_1 ((n_1 + n_2)T - t^*)}.
\]

Thus,
\[
 z\left((n_1' + n_2 + n_3)T\right) \geq z\left((n_1' + n_2)T\right) e^{n_1} n^3 \\
\geq m_3 \left(1 - \rho\right) e^{n_1} \left(1 + n_3\right) e^{n_3} n^3, \\
> m_3,
\]
which is a contradiction. Therefore, we obtain \( z(t^*) > m_3 \) for some \( t^* \in [n_1' + 1)T, (n_1' + 1)T + T' \].

Next, we assume that \( \bar{r} = \inf \{z(t) > m_3\} \). Then, we have \( z(t) \leq m_3 \) for \( t \in \left[ t^*, \bar{r}\right] \) and \( z(\bar{r}) = m_3 \). Suppose that \( t \in (n_1'T + (l' - 1)T, n_1'T + l'T) \) and a positive number \( l' \) is chosen for which \( l' \leq n_2 + n_1 + 1 \). From (54), we obtain
\[
 z(t) \geq z\left(n_1'T + (l' - 1)T\right) e^{n_1\left(l' - (n_1'T + (l' - 1)T)\right)} \\
= z\left(n_1'T + (l' - 1)T\right) e^{n_1\left(l' - (n_1'T + (l' - 1)T)\right)}.
\]

Therefore,
\[
 z(t) \geq z\left(n_1'T + (l' - 1)T\right) (1 - \rho)^{l'-1} e^{n_1\left(l' - (n_1'T + (l' - 1)T)\right)} \\
\geq z(t^*) (1 - \rho)^{l'-1} e^{n_1\left(l' - (n_1'T + (l' - 1)T)\right)} \\
\geq m_3 (1 - \rho)^{l'-1} e^{n_1\left(l' - (n_1'T + (l' - 1)T)\right)}.
\]

Since \( n_1'T + (l' - 1)T < t \leq n_1'T + l'T \) and \( n_1'T < t < (n_1' + 1)T \), we then obtain \( t - t^* \leq (n_2 + n_1 + 1)T \).

Thus,
\[
 z(t) \geq m_3 (1 - \rho)^{n_2 + n_1 + 1} e^{n_1\left(n_1' + n_2 + n_1 + 1\right)T}.
\]

We let
\[
m_2 = m_3 (1 - \rho)^{n_2 + n_1 + 1} e^{n_1\left(n_1' + n_2 + n_1 + 1\right)T}.
\]

It follows that \( z(t) \geq m_2 \) for \( t \in (t^*, \bar{r}) \). We can use \( \bar{r} \) instead of \( t^* \), the proof can be proceeded in the same manner, and consequently, we will obtain \( z(t) \geq m_2 \) for sufficiently large \( t \).

Case 2.2: there exists \( t'' \in (t^*, (n_1' + 1)T) \) such that \( z(t'') > m_3 \). We assume that \( \bar{r} = \inf \{z(t) > m_3\} \). Then, we have \( z(t) < m_3 \) for \( t \in [t^*, \bar{r}] \); and \( z(\bar{r}) = m_3 \). Since \( t < (n_1' + 1)T < t^* + T \), for \( t \in [t^*, \bar{r}] \), we obtain the following:
\[
 z(t) \geq z(t^*) e^{n_1\left(t - t^*\right)} \\
\geq m_2 e^{n_1T} \\
= m_2.
\]

Since \( z(t) \geq m_3 \), we can proceed the proof in the same manner for \( t > \bar{r} \). We then have \( z(t) \geq m_2 \) for \( t \geq t_1 \) because \( m_2 > m_3 \) and the proof is complete.

5. Periodic Solution: Existence and Stability

To investigate the possibility of a bifurcation of the nontrivial periodic solution to systems (5) and (6) near \((0, \bar{w}(t))\), we first interchange the variables of \( z \) and \( w \) for convenience on computation. In what follows, let us consider the following system instead:
\[
\frac{dz}{dt} = a_7 f_1(w) - a_8 f_1(w)z k_5 + f_1(w) - k_6 + f_2(w)b_4z \\
\frac{dw}{dt} = \left(\frac{a_5 f_1(w)}{k_3 + f_1^2(w)} + \frac{a_6 f_2(w)}{k_4 + f_2^2(w)}\right)zw - b_3w,
\]
with
\[
\Delta z(t) = \mu, \\
\Delta w(t) = -\rho w(t), \quad t \neq nT.
\]

Let
\[
G_1(z, w) = a_7 f_1(w) - a_8 f_1(w)z k_5 + f_1(w) - k_6 + f_2(w)b_4z, \\
G_2(z, w) = \left(\frac{a_5 f_1(w)}{k_3 + f_1^2(w)} + \frac{a_6 f_2(w)}{k_4 + f_2^2(w)}\right)zw - b_3w.
\]

Note that
\[
f_1(w) = \frac{a_1 b_2}{A(k_1 + w)} + \frac{a_2 a_3}{A(k_2 + w)}, \\
f_1'(w) = -\left(\frac{a_1 b_2}{A(k_1 + w)^2} + \frac{a_1 a_3}{A(k_2 + w)^2}\right), \\
f_2(w) = \frac{a_3}{b_2(k_2 + w)} + \frac{a_1 b_4}{A(k_1 + w) + \frac{a_2 a_4}{A(k_2 + w)}}, \\
f_2'(w) = -\left(\frac{a_3}{b_2(k_2 + w)^2} + \frac{a_1 a_4}{A(k_1 + w)^2} + \frac{a_1 a_3 a_4}{A(k_2 + w)^2}\right).
\]

According to Lakmeche and Ario [45], the following notations are used:
\[
\begin{align*}
\frac{\partial \Phi_1}{\partial w} &= \frac{\partial \Phi_2}{\partial z} = 0, \\
\frac{\partial \Phi_1}{\partial z} &= 1, \\
\frac{\partial \Phi_2}{\partial w} &= 1 - \rho, \\
\frac{\partial^2 \Phi_1}{\partial z \partial w} &= \frac{\partial^2 \Phi_2}{\partial z \partial w} = \frac{\partial^2 \Phi_1}{\partial z^2} = \frac{\partial^2 \Phi_2}{\partial z^2},
\end{align*}
\]

(73)

\[
\begin{align*}
\Theta_1 (z, w) &= z + \mu, \\
\Theta_2 (z, w) &= (1 - \rho)w, \\
\zeta (t) &= (\bar{w}(t), 0)^T, \\
S_0 &= (\bar{w}(\tau_0), 0)^T, \\
\tau_0 &= T_{\text{max}}.
\end{align*}
\]

\[
\begin{align*}
\frac{\partial G_1 (\zeta (r))}{\partial z} &= \frac{a_k f_1 (0)}{k_3 + f_1 (0)} - \frac{a_k f_2 (0)}{k_6 + f_2 (0)} - b_4 = -C, \\
\frac{\partial G_2 (\zeta (r))}{\partial w} &= \frac{a_k f_1 (0)}{k_3 + f_1 (0)} + \frac{a_k f_2 (0)}{k_4 + f_2 (0)} \bar{w} (r) - b_3 = D \bar{w} (r) - b_3, \\
\frac{\partial G_1 (\zeta (r))}{\partial w} &= a_k f_1 (0) - a_k \bar{w} (r) \left( \frac{f_1 (0)}{k_5 + f_1 (0)} - \frac{f_1 (0)f_1 (0)}{(k_5 + f_1 (0))^2} \right) - a_k \bar{w} (r) \left( \frac{f_1 (0)}{k_6 + f_2 (0)} - \frac{f_1 (0)f_2 (0)}{(k_6 + f_2 (0))^2} \right), \\
\frac{\partial G_2 (\zeta (r))}{\partial z \partial w} &= \frac{a_k f_1 (0)}{k_3 + f_1 (0)} + \frac{a_k f_2 (0)}{k_4 + f_2 (0)} D, \\
\frac{\partial G_2 (\zeta (r))}{\partial \omega} &= 2a_k \bar{w} (r) \left( \frac{f_1 (0)}{k_5 + f_1 (0)} - \frac{f_1 (0)f_1 (0)}{(k_5 + f_1 (0))^2} \right) + 2a_k \bar{w} (r) \left( \frac{f_1 (0)}{k_6 + f_2 (0)} - \frac{f_1 (0)f_2 (0)}{(k_6 + f_2 (0))^2} \right), \\
\frac{\partial \Phi_1 (\tau_0, S_0)}{\partial \tau} &= \frac{\partial \bar{w} (\tau_0, S_0)}{\partial t} = \frac{-C \mu \exp (-C \tau_0)}{1 - \exp (-C \tau_0)} < 0, \\
\frac{\partial \Phi_1 (\tau_0, S_0)}{\partial \omega} &= \exp \left( \int_0^{\tau_0} \frac{\partial G_1 (\zeta (r))}{\partial z} \, dr \right) = \exp (-C \tau_0) > 0, \\
\frac{\partial \Phi_1 (\tau_0, S_0)}{\partial \omega} &= \int_0^{\tau_0} \exp \left( \int_0^v \frac{\partial G_1 (\zeta (r))}{\partial z} \, dr \right) \frac{\partial G_1 (\zeta (v))}{\partial w} \exp \left( \int_0^v \frac{\partial G_2 (\zeta (r))}{\partial w} \, dr \right) \, dv \\
&= \int_0^{\tau_0} \exp \left( -C (\tau_0 - v) \right) \times \left( \frac{a_k f_1 (0)}{k_5 + f_1 (0)} - \frac{a_k f_1 (0)f_1 (0)}{(k_5 + f_1 (0))^2} \right) \\
&= \int_0^{\tau_0} \exp \left( -C (\tau_0 - v) \right) \times \left( a_k \bar{w} (r) \left( \frac{f_1 (0)}{k_5 + f_1 (0)} - \frac{f_1 (0)f_1 (0)}{(k_5 + f_1 (0))^2} \right) \right) \exp \left( \int_0^r \exp \left( (D \bar{w} (r) - b_3) \, dr \right) \right) \, dv, \\
\frac{\partial \Phi_2 (\tau_0, S_0)}{\partial \omega} &= \exp \left( \int_0^{\tau_0} \frac{\partial G_2 (\zeta (r))}{\partial w} \, dr \right) = \exp \left( \int_0^{\tau_0} (D \bar{w} (r) - b_3) \, dr \right) > 0, \\
\frac{\partial^2 \Phi_1 (\tau_0, S_0)}{\partial \omega} &= \int_0^{\tau_0} \exp \left( \int_0^v \frac{\partial G_2 (\zeta (r))}{\partial w} \, dr \right) \frac{\partial^2 G_2 (\zeta (v))}{\partial z \partial w} \exp \left( \int_0^v \frac{\partial G_1 (\zeta (r))}{\partial w} \, dr \right) \, dv \\
&= \int_0^{\tau_0} \exp \left( \int_0^v \frac{\partial G_2 (\zeta (r))}{\partial w} \, dr \right) \frac{\partial^2 G_2 (\zeta (v))}{\partial z \partial w} \exp \left( \int_0^v \frac{\partial G_1 (\zeta (r))}{\partial w} \, dr \right) \, dv.
\end{align*}
\]
\[
\frac{\partial^2 \Phi_2 (r_0, S_0)}{\partial w^2} = \int_0^{r_0} \exp \left( \int_v^r \frac{\partial G_2 (\zeta (r))}{\partial w} \right) \frac{\partial^2 G_2 (\zeta (v))}{\partial w^2} \exp \left( \int_0^{r_0} \frac{\partial G_2 (\zeta (r))}{\partial w} \right) \, dv \\
+ \int_0^{r_0} \left[ \exp \left( \int_v^{r_0} \frac{\partial G_2 (\zeta (r))}{\partial w} \right) \frac{\partial^2 G_2 (\zeta (r))}{\partial z \partial w} \right] \times \left[ \int_0^{r_0} \exp \left( \int_0^{r_0} \frac{\partial G_1 (\zeta (\theta))}{\partial w} \right) \frac{\partial G_1 (\zeta (\theta))}{\partial w} \exp \left( \int_0^{r_0} \frac{\partial G_2 (\zeta (r))}{\partial w} \right) \, d\theta \right] \, dv,
\]
\[
= (D \bar{w} (r_0) - b_3) \exp \left( \int_0^{r_0} (D \bar{w} (r) - b_3) \, dr \right).
\]

\[
\frac{\partial^2 \Phi_2 (r_0, S_0)}{\partial w \partial \tau} = \frac{\partial G_2 (\zeta (r_0))}{\partial w} \exp \left( \int_0^{r_0} \frac{\partial G_2 (\zeta (r))}{\partial w} \right) \\
\]

Now, we can compute
\[
d'_0 = 1 - \left( \frac{\partial \Theta_2}{\partial w} \frac{\partial \Phi_2}{\partial w} \right)_{(r_0, S_0)} = 1 - \exp (-C r_0) > 0,
\]

where \( r_0 \) is the root of \( d'_0 = 0 \) and
\[
d'_0 = 1 - (1 - \rho) \exp \left( \int_0^{r_0} (D \bar{w} (r) - b_3) \, dr \right).
\]
We can see that $I > 0$ if

$$T > \frac{1}{C} \ln \left( 1 + \frac{\mu C D}{b_3 C - B D} \right),$$

(77)

$$\mu < \frac{B}{C} \frac{b_3}{D},$$

(78)

while $I < 0$ provided that (19) and

$$\frac{B}{C} (K_1 + K_2) > K_0,$$

(79)

$$k_3 < f_1'(0),$$

(80)

$$k_4 < f_2'(0),$$

(81)

hold where $K_0 = a_2 f_1'(0), K_1 = -(a_9 k_5 f_1'(0) / (k_6 + f_1'(0))^2)$ and $K_2 = -(a_9 k_6 f_2'(0) / (k_6 + f_2'(0))^2)$.

This leads to the following theorem according to Lakmeche and Ario [45].

**Theorem 3.** If (19), (77), and (78) hold, then systems (5) and (6) have a positive periodic solution.

6. Numerical Simulations

In this section, numerical simulations are performed to illustrate the theoretical predictions as proved in the previous section.

To illustrate the theoretical prediction in Theorem 1, the parameters in systems (5) and (6) are chosen to satisfy the conditions in (18) and (20) as follows: $a_1 = 0.32, a_2 = 0.58, a_4 = 0.19, a_5 = 0.39, a_6 = 0.1, a_7 = 0.34, a_8 = 0.03$, $b_1 = 0.98, b_2 = 0.68, b_3 = 0.25, b_4 = 0.15, k_1 = 0.56, k_2 = 0.95, k_3 = 0.96, k_4 = 0.99, k_5 = 0.84, k_6 = 0.65, \mu = 0.01, \rho = 0.2, T = 1, z(0) = 0.1$, and $w(0) = 0.1$ in which all conditions in Theorem 1 are satisfied.

To illustrate the theoretical prediction in Theorem 2, the parameters in systems (5) and (6) are chosen to satisfy the conditions in (10), (19), and (30) as follows: $a_1 = 0.32, a_2$
The computer simulation is shown in Figure 3. We can see that the solution of systems (5) and (6) exhibits sustained oscillations as predicted in Theorem 3.

In addition, to illustrate the effect of different periods between each estrogen administration, computer simulations of systems (5) and (6) for $T = 1, 1.5, 2, 2.5, 3$ when $a_1 = 0.32, a_2 = 0.58, a_4 = 0.19, a_4 = 0.39, a_5 = 0.1, a_6 = 0.34, a_7 = 0.91, a_7 = 0.91, a_8 = 0.03, b_1 = 0.98, b_2 = 0.68, b_3 = 0.01, b_4 = 0.5, k_1 = 0.56, k_2 = 0.95, k_3 = 0.96, k_4 = 0.99, k_5 = 0.84, k_6 = 0.65, \mu = 0.1, \rho = 0.1, T = 5, z(0) = 0.1, \text{and } w(0) = 0.1$ are as shown in Figure 4.

As shown in Figure 4, we can see that the period between each estrogen administration $T$ is significant. The smaller value of $T$ yields the better result on the number of osteoclasts and osteoblasts.
Figure 3: A computer simulation of systems (5) and (6). The solution exhibits sustained oscillations. Here, $a_1 = 0.32, a_2 = 0.58, a_3 = 0.19, a_4 = 0.39, a_5 = 0.1, a_6 = 0.34, a_7 = 0.91, a_8 = 0.7, a_9 = 0.03, b_1 = 0.98, b_2 = 0.68, b_3 = 0.01, b_4 = 0.5, k_1 = 0.56, k_2 = 0.95, k_3 = 0.96, k_4 = 0.2, k_5 = 0.84, k_6 = 0.65, \mu = 0.1, \rho = 0.1, T = 10, z(0) = 0.1, \text{ and } w(0) = 0.1$, in which all conditions in Theorem 3 are satisfied.
7. Conclusion

In this paper, an impulsive mathematical model of the process of bone remodeling accounted for bone-resorbing cells, osteoclasts, and bone-forming cells, osteoblasts, is developed in order to investigate the effect of impulsive estrogen supplement. The effects of parathyroid hormone and prolactin are also taken into account. We then apply the Floquet theory and the comparison theorem to derive the conditions in which the periodic solution is locally asymptotically stable. Moreover, the permanence of the system is also investigated as well so that we arrived at the conditions for which the sustained oscillation of the solution is guaranteed. In addition, computer simulations are presented to illustrate the theoretical predictions. The results indicate that the dosage of estrogen supplement indicated by $\mu$ and $\rho$ and the frequency of estrogen supplement indicated by $1/T$ play important roles in the treatment of osteoporosis patients. Even though the smaller value of $T$ yields the better result on the number of osteoclasts and osteoblasts, the side effects of estrogen administration are also needed to take into account. Therefore, the appropriate dosage and frequency of estrogen supplement that could control the number of bone-forming cells and bone-resorbing cells to lie within the desirable range might lead to an efficient treatment in osteoporosis patients.

Data Availability

The data/information supporting the formulation of the mathematical model in this paper are/is from previously reported studies and datasets, which have been cited in the paper.
Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

This work was supported by the Centre of Excellence in Mathematics, Thailand, Mahidol University, Thailand, and the Science Achievement Scholarship of Thailand (SAST).

References

[1] F. Cosman, S. J. de Beur, M. S. LeBoff et al., “Clinician’s guide to prevention and treatment of osteoporosis,” Osteoporosis International, vol. 25, no. 10, pp. 2359–2381, 2014.
[2] W. S. Group, “Prevention and management of osteoporosis,” World Health Organization Technical Report Series, vol. 921, pp. 38–81, 2003.
[3] H. D. Nelson, C. D. Morris, D. F. Kraemer et al., “Osteoporosis in postmenopausal women: diagnosis and monitoring,” Evidence Report/Technology Assessment (Summary), vol. 28, pp. 1-2, 2001.
[4] NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis, and Therapy,” Osteoporosis prevention, diagnosis, and therapy,” Journal of the American Medical Association: The Journal of the American Medical Association, vol. 285, no. 6, pp. 785–795, 2001.
[5] T. D. Rachner, S. Khosla, and L. C. Hofbauer, “Osteoporosis: now and the future,” The Lancet, vol. 377, no. 9773, pp. 1276–1287, 2011.
[6] M.-X. Ji and Q. Yu, “Primary osteoporosis in postmenopausal women,” Chronic diseases and translational medicine, vol. 1, no. 1, pp. 9–13, 2015.
[7] C. Cooper, G. Campion, and L. J. Melton 3rd, “Hip fractures in the elderly: a world-wide projection,” Osteoporosis International, vol. 2, no. 6, pp. 285–289, 1992.
[8] J.-Y. Reginster and N. Burlet, “Osteoporosis: a still increasing prevalence,” Bone, vol. 38, no. 2, pp. 4–9, 2006.
[9] K. K. Limphaphayom, N. Taechawaiachana, U. Jaisamarran et al., “Prevalence of osteopenia and osteoporosis in Thai women,” Menopause, vol. 8, no. 1, pp. 65–69, 2001.
[10] T. Sözen, L. Öziş, and N. Ç Başaran, “An overview and management of osteoporosis,” European Journal of Rheumatology, vol. 4, no. 1, pp. 46–56, 2017.
[11] R. Florencio-Silva, G. Rodrigues da Silva Sasso, E. Sasso-Cerri, M. Jesus Simões, and P. Sérgio Cerri, "Bone tissue: structure, function, and factors that influence bone cells," BioMed Research International, vol. 2015, Article ID 721746, 17 pages, 2015.
[12] United States Public Health Service, Bone Health and Osteoporosis: A Report of the Surgeon General, University Press of the Pacific, Honolulu, HI, USA, 2004.
[13] S. Jerez, S. Díaz-Infante, and B. Chen, “Fluctuating periodic solutions and moment boundedness of a stochastic model for the bone remodeling process,” Mathematical Biosciences, vol. 299, pp. 153–164, 2018.
[14] Y. T. Isogai, T. Akatsu, T. Ishizuya et al., “Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on differentiation stages,” Journal of Bone and Mineral Research, vol. 11, pp. 1384–1393, 1996.
[15] J. E. Oniaya, J. Bidwell, J. Herring, J. Hulman, and J. M. Hock, “In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats,” Bone, vol. 17, pp. 479–484, 1995.
[16] T. Ishizuya, S. Yokose, M. Hori et al., “Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells,” Journal of Clinical Investigation, vol. 99, no. 12, pp. 2961–2970, 1997.
[17] M. Kroll, “Parathyroid hormone temporal effects on bone formation and resorption,” Bulletin of Mathematical Biology, vol. 62, no. 1, pp. 163–188, 2000.
[18] D. W. Dempster, F. Cosman, M. Parisien, V. Shen, and R. Lindsay, “Anabolic actions of parathyroid hormone on bone,” Endocrine Reviews, vol. 14, no. 6, pp. 690–709, 1993.
[19] M. E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy, “Prolactin: structure, function, and regulation of secretion,” Physiological Reviews, vol. 80, no. 4, pp. 1523–1631, 2000.
[20] P. Clément-Lacroix, C. Ormandy, L. Lepescheux et al., “Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice,” Endocrinology, vol. 140, no. 1, pp. 96–105, 1999.
[21] N. Charoenphandhu, K. Tudpor, K. Thongchote, W. Saengamart, S. Puntheeranurak, and N. Krishnamra, “High-calcium diet modulates effects of long-term prolactin exposure on the cortical bone calcium content in ovariec- tomized rats,” American Journal of Physiology-Endocrinology and Metabolism, vol. 292, no. 2, pp. E443–E452, 2007.
[22] H. M. Frost, “On the estrogen-bone relationship and post- menopausal bone loss: a new model,” Journal of Bone and Mineral Research, vol. 14, no. 9, pp. 1473–1477, 1999.
[23] Y. Miyazaki, Y. Sato, T. Kobayashi et al., “HIF1 is required for osteoclast activation by estrogen deficiency in postmeno- pausal osteoporosis,” Proceedings of the National Academy of Sciences, vol. 110, no. 41, pp. 16568–16573, 2013.
[24] D. Merlotti, L. Gennari, K. Stolakis, and R. Nuti, “Aromatase activity and bone loss in men,” Journal of Osteoporosis, vol. 2011, Article ID 230671, 11 pages, 2011.
[25] J. A. Kants, “Treatment of osteoporosis in elderly women,” The American Journal of Medicine, vol. 98, no. 2, pp. 60S–66S, 1995.
[26] B. L. Riggs and L. J. Melton, Osteoporosis: Etiology, Diagnosis, and Management, Lippincott Williams & Wilkins, Philadelphia, PA, USA, 1995.
[27] M. E. Davis, N. M. Strandjord, and L. H. Lanzl, “Estrogens and the aging process,” Jama, vol. 196, no. 3, pp. 219–224, 1966.
[28] C. Ciani, D. Sharma, S. B. Doty, and S. P. Fritton, “Ovariectomy enhances mechanical load-induced solute transport around osteocytes in rat cancellous bone,” Bone, vol. 59, pp. 229–234, 2014.
[29] M. Chadong, Y. Lenbury, and C. Rattanakul, “Stability, permanence and positive periodicity in a model of bone remodeling under impulsive PTH control,” International Journal of Mathematical Models and Methods in Applied Sciences, vol. 5, pp. 77–86, 2011.
[30] C. Rattanakul, Y. Lenbury, N. Krishnamara, and D. J. Wollkind, “Modeling of bone formation and resorption mediated by parathyroid hormone: response to estrogen/PTH therapy,” Biosystems, vol. 70, no. 1, pp. 55–72, 2003.
[31] C. Rattanakul and S. Rattanamongkonkul, “Effect of calci- tonin on bone formation and resorption: mathematical modeling approach,” System, vol. 3, no. 4, p. 2, 2011.
[32] W. Panitsupakamon and C. Rattanakul, “A delay-differential equation model of bone remodeling process: effects of es- trogen supplements,” International Journal of Mathematics and Computer Science, vol. 6, pp. 430–438, 2012.
[33] I. Chaiya and C. Rattanakul, “Effects of prolactin on bone remodeling process with parathyroid hormone supplement: an impulsive mathematical model,” Advances in Difference Equations, vol. 2017, p. 147, 2017.

[34] I. Chaiya and C. Rattanakul, “An impulsive mathematical model of bone formation and resorption: effects of parathyroid hormone, calcitonin and impulsive estrogen supplement,” Advances in Difference Equations, vol. 2017, no. 1, p. 153, 2017.

[35] J. A. Albright and M. Sauders, The Scientific Basis of Orthopaedics, Appleton & Lange, Norwalk, Connecticut, 1987.

[36] H. M. Goodman, Basic Medical Endocrinology, Elsevier Limited, Amsterdam, Netherlands, 2009.

[37] J. P. Raymond, R. Isaac, R. E. Mercer, and F. Wahbe, “Comparison between the plasma concentrations of prolactin and parathyroid hormone in normal subjects and in patients with hyperparathyroidism or hyperprolactinemia,” Journal of Clinical Endocrinology & Metabolism, vol. 55, no. 6, pp. 1222–1225, 1982.

[38] G. Weryha and J. Leclère, “Paracrine regulation of bone remodeling,” Hormone Research, vol. 43, no. 1-3, pp. 69–75, 1995.

[39] P. Morley, J. Whitfield, and G. Willick, “Parathyroid hormone an anabolic treatment for osteoporosis,” Current Pharmaceutical Design, vol. 7, no. 8, pp. 671–687, 2001.

[40] J. F. Whitfield, P. Morley, and G. E. Willick, The Parathyroid Hormone: An Unexpected Bone Builder for Treating Osteoporosis, Landes Bioscience Company, Austin, TX, USA, 1998.

[41] D. Seriwatanachai, N. Krishnamra, and J. P. T. M. van Leeuwen, “Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization,” Journal of Cellular Biochemistry, vol. 107, no. 4, pp. 677–685, 2009.

[42] S. Karstrup, L. Hegedüs, and H. H. Holm, “Acute change in parathyroid function in primary hyperparathyroidism following ultrasonically guided ethanol injection into solitary parathyroid adenomas,” Acta Endocrinologica, vol. 129, no. 5, pp. 377–380, 1993.

[43] K. Prank, H. Harms, M. Dammig, G. Brabant, F. Mitschke, and R. D. Hesch, “Is there low-dimensional chaos in pulsatile secretion of parathyroid hormone in normal human subjects?” American Journal of Physiology-Endocrinology and Metabolism, vol. 266, no. 4, pp. E653–E658, 1994.

[44] V. Lakshmikantham and P. S. Simeonov, Theory of Impulsive Differential Equations, Vol. 6, World Scientific, Singapore, 1989.

[45] A. Lakmeche and O. Ario, “Birfurcation of non trivial periodic solutions of impulsive differential equations arising chemotherapeutic treatment,” Dynamics of Continuous, Discrete and Impulsive Systems, vol. 7, pp. 265–287, 2000.